Literature DB >> 32869115

Method for preservation of DNA stability of liquid-based cytology specimens from a lung adenocarcinoma cell line.

Yukiko Matsuo1, Kazuya Yamashita2, Tsutomu Yoshida2,3, Yukitoshi Satoh4.   

Abstract

Liquid-based cytology (LBC) specimens of lung adenocarcinoma have the potential to be widely used for genetic analysis. However, formaldehyde contained in some LBC preservation solutions can cause DNA fragmentation during specimen storage, rendering the samples unsuitable for molecular analysis. To investigate a novel preservation technique for improved DNA stability, which was evaluated by mutation analysis of epidermal growth factor receptor (EGFR) gene in human lung adenocarcinoma cell lines. Cells were fixed in CytoRich Red preservation solution. After 30 min of fixation, cells were either stored using the conventional method (suspended in preservation solution) or washed in phosphate-buffered saline and stored as a cell pellet (newly proposed method). The effect of storage was evaluated after 5, 7, and 9 days of storage at ambient temperature. The cell pellet group was also tested after 14 and 28 days. Specifically, we evaluated the DNA stability, DNA yield, and sample suitability for polymerase chain reaction (PCR), and EGFR mutation detection. The DNA yields and degree of stability from the cell pellet group were higher than those from the suspension group at every time point examined. PCR amplification from the cell pellet group was successful up to day 28. Mutation detection using the Cycleave PCR method indicated that the Ct values of the cell pellet group were significantly lower than those of the suspension group. Storing LBC specimens as a cell pellet post-fixation can maintain the DNA quality for a longer period than the conventional method, making it a promising strategy for molecular analysis.

Entities:  

Keywords:  Cell pellet; DNA stability; Epidermal growth factor receptor; Liquid-based cytology; Lung cancer

Year:  2020        PMID: 32869115     DOI: 10.1007/s00428-020-02919-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Dara L Aisner; Maria E Arcila; Mary Beth Beasley; Eric H Bernicker; Carol Colasacco; Sanja Dacic; Fred R Hirsch; Keith Kerr; David J Kwiatkowski; Marc Ladanyi; Jan A Nowak; Lynette Sholl; Robyn Temple-Smolkin; Benjamin Solomon; Lesley H Souter; Erik Thunnissen; Ming S Tsao; Christina B Ventura; Murry W Wynes; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2018-01-25       Impact factor: 15.609

5.  Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population.

Authors:  Annie N Y Cheung; Elaine F Szeto; Betty S Y Leung; Ui-Soon Khoo; Anita W Y Ng
Journal:  Cancer       Date:  2003-12-25       Impact factor: 6.860

6.  A comparison of liquid-based cytology with conventional cytology in cervical cancer screening.

Authors:  Setsu Akamatsu; Shoji Kodama; Yukari Himeji; Naomi Ikuta; Nikako Shimagaki
Journal:  Acta Cytol       Date:  2012-07-25       Impact factor: 2.319

7.  Cytologic detection of cervical abnormalities using liquid-based compared with conventional cytology: a randomized controlled trial.

Authors:  Albertus G Siebers; Paul J J M Klinkhamer; Marc Arbyn; Amidu O Raifu; Leon F A G Massuger; Johan Bulten
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.661

8.  Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.

Authors:  Guglielmo Ronco; Jack Cuzick; Paola Pierotti; Maria Paola Cariaggi; Paolo Dalla Palma; Carlo Naldoni; Bruno Ghiringhello; Paolo Giorgi-Rossi; Daria Minucci; Franca Parisio; Ada Pojer; Maria Luisa Schiboni; Catia Sintoni; Manuel Zorzi; Nereo Segnan; Massimo Confortini
Journal:  BMJ       Date:  2007-05-21

Review 9.  The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Authors:  Daniel S W Tan; Sue S Yom; Ming S Tsao; Harvey I Pass; Karen Kelly; Nir Peled; Rex C Yung; Ignacio I Wistuba; Yasushi Yatabe; Michael Unger; Philip C Mack; Murry W Wynes; Tetsuya Mitsudomi; Walter Weder; David Yankelevitz; Roy S Herbst; David R Gandara; David P Carbone; Paul A Bunn; Tony S K Mok; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-05-23       Impact factor: 15.609

10.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

View more
  1 in total

1.  Impact of LBC Fixative Type and Fixation Time on Molecular Analysis of Pancreatic Cancer Cells: A Comparative Study of Cell Morphology, Antigenicity and Nucleic Acids.

Authors:  Junya Izuhara; Kazuki Kanayama
Journal:  J Cytol       Date:  2022-05-20       Impact factor: 1.577

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.